Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING: Hydroxyurea for Stroke Prevention in Sickle Cell Anemia
NCT02560935Phase 3Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jul 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydroxyurea in sickle cell anemia (SCA), sponsored by Vanderbilt University Medical Center. Started Jul 2016; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT02560935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560935.